Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".

He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M.

Am J Surg Pathol. 2011 Apr;35(4):608-14. doi: 10.1097/PAS.0b013e31820bcd2d.

PMID:
21383613
2.

The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.

Shah RB, Tadros Y, Brummell B, Zhou M.

Hum Pathol. 2013 May;44(5):786-94. doi: 10.1016/j.humpath.2012.06.024. Epub 2012 Nov 14.

PMID:
23158212
3.

The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.

Yaskiv O, Zhang X, Simmerman K, Daly T, He H, Falzarano S, Chen L, Magi-Galluzzi C, Zhou M.

Am J Surg Pathol. 2011 Jul;35(7):1062-8. doi: 10.1097/PAS.0b013e318215cc03.

PMID:
21623182
4.

Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.

He H, Osunkoya AO, Carver P, Falzarano S, Klein E, Magi-Galluzzi C, Zhou M.

BJU Int. 2012 Dec;110(11 Pt B):E751-5. doi: 10.1111/j.1464-410X.2012.11557.x. Epub 2012 Oct 9.

5.

Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP.

Arch Pathol Lab Med. 2012 Aug;136(8):935-46. doi: 10.5858/arpa.2011-0424-OA.

6.

ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia.

Shah RB, Li J, Dhanani N, Mendrinos S.

Urol Oncol. 2016 Mar;34(3):120.e1-7. doi: 10.1016/j.urolonc.2015.10.008. Epub 2015 Nov 14.

PMID:
26585946
7.

Clinicopathological features of prostate cancers detected after an initial diagnosis of 'atypical glands suspicious for cancer'.

Zhou M, Magi-Galluzzi C.

Pathology. 2010 Jun;42(4):334-8. doi: 10.3109/00313021003767280.

PMID:
20438405
8.

ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications.

Lee SL, Yu D, Wang C, Saba R, Liu S, Trpkov K, Donnelly B, Bismar TA.

Appl Immunohistochem Mol Morphol. 2015 Aug;23(7):499-505. doi: 10.1097/PAI.0000000000000119.

PMID:
25517865
9.

Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Epstein JI, Egevad L, Humphrey PA, Montironi R; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group.

Am J Surg Pathol. 2014 Aug;38(8):e6-e19. doi: 10.1097/PAS.0000000000000238.

PMID:
25029122
10.
11.

Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.

Zhou M, Shah R, Shen R, Rubin MA.

Am J Surg Pathol. 2003 Mar;27(3):365-71.

PMID:
12604893
12.

Lack of ERG-antibody in Benign Mimickers of Prostate Cancer.

Bachurska SY, Staykov DG, Ivanov GP, Belovezhdov VT.

Folia Med (Plovdiv). 2016 Mar 1;58(1):48-53. doi: 10.1515/folmed-2016-0007.

PMID:
27383878
13.

Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.

Green WM, Hicks JL, De Marzo A, Illei PP, Epstein JI.

Hum Pathol. 2013 Sep;44(9):1895-901. doi: 10.1016/j.humpath.2013.02.019. Epub 2013 May 9.

PMID:
23664537
14.

ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.

Gao X, Li LY, Zhou FJ, Xie KJ, Shao CK, Su ZL, Sun QP, Chen MK, Pang J, Zhou XF, Qiu JG, Wen XQ, Yang M, Bai XZ, Zhang H, Ling L, Chen Z.

Clin Cancer Res. 2012 Aug 1;18(15):4163-72. Epub 2012 Jun 13.

15.

Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.

Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.

Hum Pathol. 2004 Dec;35(12):1462-8.

PMID:
15619204
16.

Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.

Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA.

Am J Surg Pathol. 2002 Sep;26(9):1161-8.

PMID:
12218572
17.

[Benign mimickers of the prostate cancer. Diagnostic challenges].

Compérat E, Varinot J, Srigley JR.

Ann Pathol. 2013 Aug;33(4):237-46. doi: 10.1016/j.annpat.2013.06.005. Epub 2013 Jul 31. Review. French.

PMID:
23954116
18.

Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.

Shah RB, Bentley J, Jeffery Z, DeMarzo AM.

Hum Pathol. 2015 May;46(5):698-706. doi: 10.1016/j.humpath.2015.01.008. Epub 2015 Jan 29.

PMID:
25724568
19.
20.

TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA.

J Clin Oncol. 2014 Jan 20;32(3):206-11. doi: 10.1200/JCO.2013.49.8386. Epub 2013 Dec 2.

Supplemental Content

Support Center